Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
GDMC has secured $21 million in growth capital funding to expand its global design and manufacturing operations for genetic medicines. The company has begun construction of a large facility in Singapore intended to support preclinical through commercial-scale production of cell, gene, and nucleic acid therapies. It has signed initial clients with facilities expected to open between 2024–2027. No direct clinical results are reported as it operates as an enabler/CDMO rather than developing proprietary therapeutics.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on GDMC.